326 related articles for article (PubMed ID: 19654294)
1. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Sakai W; Swisher EM; Jacquemont C; Chandramohan KV; Couch FJ; Langdon SP; Wurz K; Higgins J; Villegas E; Taniguchi T
Cancer Res; 2009 Aug; 69(16):6381-6. PubMed ID: 19654294
[TBL] [Abstract][Full Text] [Related]
2. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Sakai W; Swisher EM; Karlan BY; Agarwal MK; Higgins J; Friedman C; Villegas E; Jacquemont C; Farrugia DJ; Couch FJ; Urban N; Taniguchi T
Nature; 2008 Feb; 451(7182):1116-20. PubMed ID: 18264087
[TBL] [Abstract][Full Text] [Related]
3. Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
Meghani K; Fuchs W; Detappe A; Drané P; Gogola E; Rottenberg S; Jonkers J; Matulonis U; Swisher EM; Konstantinopoulos PA; Chowdhury D
Cell Rep; 2018 Apr; 23(1):100-111. PubMed ID: 29617652
[TBL] [Abstract][Full Text] [Related]
4. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Wang W; Figg WD
Cancer Biol Ther; 2008 Jul; 7(7):1004-5. PubMed ID: 18720553
[TBL] [Abstract][Full Text] [Related]
5. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
6. Resistance to therapy caused by intragenic deletion in BRCA2.
Edwards SL; Brough R; Lord CJ; Natrajan R; Vatcheva R; Levine DA; Boyd J; Reis-Filho JS; Ashworth A
Nature; 2008 Feb; 451(7182):1111-5. PubMed ID: 18264088
[TBL] [Abstract][Full Text] [Related]
7. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
Swisher EM; Sakai W; Karlan BY; Wurz K; Urban N; Taniguchi T
Cancer Res; 2008 Apr; 68(8):2581-6. PubMed ID: 18413725
[TBL] [Abstract][Full Text] [Related]
8. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.
Stukova M; Hall MD; Tsotsoros SD; Madigan JP; Farrell NP; Gottesman MM
J Inorg Biochem; 2015 Aug; 149():45-8. PubMed ID: 26021697
[TBL] [Abstract][Full Text] [Related]
9. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
10. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
11. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
Stronach EA; Alfraidi A; Rama N; Datler C; Studd JB; Agarwal R; Guney TG; Gourley C; Hennessy BT; Mills GB; Mai A; Brown R; Dina R; Gabra H
Cancer Res; 2011 Jul; 71(13):4412-22. PubMed ID: 21571862
[TBL] [Abstract][Full Text] [Related]
12. Diverse
Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
[No Abstract] [Full Text] [Related]
13. The
Du ZH; Xia Y; Yang Q; Gao S
Technol Cancer Res Treat; 2020; 19():1533033820983289. PubMed ID: 33357097
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.
Khalique S; Pettitt SJ; Kelly G; Tunariu N; Natrajan R; Banerjee S; Lord CJ
J Pathol Clin Res; 2020 Jan; 6(1):3-11. PubMed ID: 31577852
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
16. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Cooke SL; Ng CK; Melnyk N; Garcia MJ; Hardcastle T; Temple J; Langdon S; Huntsman D; Brenton JD
Oncogene; 2010 Sep; 29(35):4905-13. PubMed ID: 20581869
[TBL] [Abstract][Full Text] [Related]
17. ras mutation and platinum resistance in human ovarian carcinomas in vitro.
Holford J; Rogers P; Kelland LR
Int J Cancer; 1998 Jul; 77(1):94-100. PubMed ID: 9639399
[TBL] [Abstract][Full Text] [Related]
18. Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
Meyer S; Stevens A; Paredes R; Schneider M; Walker MJ; Williamson AJK; Gonzalez-Sanchez MB; Smetsers S; Dalal V; Teng HY; White DJ; Taylor S; Muter J; Pierce A; de Leonibus C; Rockx DAP; Rooimans MA; Spooncer E; Stauffer S; Biswas K; Godthelp B; Dorsman J; Clayton PE; Sharan SK; Whetton AD
Cell Death Dis; 2017 Jun; 8(6):e2875. PubMed ID: 28617445
[TBL] [Abstract][Full Text] [Related]
19. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
Stronach EA; Chen M; Maginn EN; Agarwal R; Mills GB; Wasan H; Gabra H
Neoplasia; 2011 Nov; 13(11):1069-80. PubMed ID: 22131882
[TBL] [Abstract][Full Text] [Related]
20. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4.
Guillemette S; Serra RW; Peng M; Hayes JA; Konstantinopoulos PA; Green MR; Cantor SB
Genes Dev; 2015 Mar; 29(5):489-94. PubMed ID: 25737278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
